BR0211171A - Compostos quìmicos - Google Patents
Compostos quìmicosInfo
- Publication number
- BR0211171A BR0211171A BR0211171-3A BR0211171A BR0211171A BR 0211171 A BR0211171 A BR 0211171A BR 0211171 A BR0211171 A BR 0211171A BR 0211171 A BR0211171 A BR 0211171A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- halo
- alkoxy
- cycloalkyl
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- -1 -NR-6-R ~ 7 ~ Chemical group 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102400000739 Corticotropin Human genes 0.000 abstract 1
- 101800000414 Corticotropin Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
- 229960000258 corticotropin Drugs 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"COMPOSTOS QUìMICOS". A presente invenção refere-se a compostos de fórmula (I) incluindo estereoisómeros, pró - drogas e seus sais ou solvatos farmaceuticamente aceitos, em que: R é arila ou heteroarila, cada um dos quais podendo ser substituído por 1 a 4 grupos selecionados de: halogênio, alquila C1-C6, alcóxi C1-C6, halo alquila C1-C6, alquenila C2-C6, alquinila C2-C6, halo alcóxi C1-C6, -C(O)R5, nitro, -NR~ 6~R~ 7~, ciano e um grupo R~ 8~; R~ 1~ é hidrogênio, alquila C1-C6, alquenila C2-C6, alquinila C2-C6, halo alquila C1-C6, halo alcóxi C1-C6, halogênio, NR~ 6~R~ 7~ ou ciano; R~ 2~ é hidrogênio, cicloalquila C3 - C7, ou um grupo R~ 9~; R~ 3~ é cicloalquila C3-C7, ou um grupo R~ 9~; ou R~ 2~ e R~ 3~ juntos com N formam um heterociclo com 5 - 14 membros, que pode ser substituído por 1 a 3 grupos R~ 10~; R~ 4~ é hidrogênio, alquila C1-C6, halogênio ou halo alquila C1-C6; R~ 5~ é uma alquila C1-C4, -OR~ 6~ ou NR~ 6~R~ 7~; R~ 6~ é hidrogênio ou alquila C1-C6; R~ 7~ é hidrogênio ou alquila C1 - C6; R~ 8~ é um heterociclo com 5 - 6 membros, que pode ser saturado ou pode conter uma a três ligações duplas, e pode ser substituìdo por 1 ou mais grupos R~ 11~; R~ 9~ é uma alquila C1-C6 que pode ser substituída por um ou mais grupos selecionados de: cicloalquila C3-C7, alcóxi C1-C6, halo alcóxi C1-C6, hidroxila, halo alquila C1-C6; R~ 10~ é um grupo R~ 8~, cicloalquila C3-C7, alquila C1-C6, alcóxi C1-C6, halo alquila C1-C6, alquenila C2-C6, alquinila C2-C6, halo alcóxi C1-C6, hidroxIla, halogênio, nitro, ciano, C(O)NR~ 6~R~ 7~, fenila que pode ser substituìda por 1 a 4 grupos R~ 11~; R~ 11~ é cicloalquila C3-C7, alquila C1-C6, alcóxi C1-C6, halo alquila C1-C6, alquenila C2-C6, alquinila C2-C6, halo alcóxi C1-C6, hidroxila, halogênio, nitro, ciano, ou C(O)NR~ 6~R~ 7~; X é carbono ou nitrogênio; n é 1 ou 2; a processos para sua preparação, a composições farmacêuticas contendo as mesmas e a seu uso no tratamento de condições mediadas por fator de liberação de corticotropina (CRF).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0117396.2A GB0117396D0 (en) | 2001-07-17 | 2001-07-17 | Chemical compounds |
| PCT/EP2002/007865 WO2003008412A2 (en) | 2001-07-17 | 2002-07-15 | Hetero-bicyclic crf antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0211171A true BR0211171A (pt) | 2004-08-10 |
Family
ID=9918655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0211171-3A BR0211171A (pt) | 2001-07-17 | 2002-07-15 | Compostos quìmicos |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7253284B2 (pt) |
| EP (2) | EP1695974B1 (pt) |
| JP (1) | JP4459616B2 (pt) |
| KR (2) | KR20090110386A (pt) |
| CN (1) | CN100447141C (pt) |
| AT (2) | ATE461197T1 (pt) |
| AU (1) | AU2002328899B2 (pt) |
| BR (1) | BR0211171A (pt) |
| CA (1) | CA2451530A1 (pt) |
| CO (1) | CO5550437A2 (pt) |
| CY (1) | CY1105780T1 (pt) |
| DE (2) | DE60214401T2 (pt) |
| DK (1) | DK1425280T3 (pt) |
| ES (2) | ES2271327T3 (pt) |
| GB (2) | GB0117396D0 (pt) |
| HK (1) | HK1066535A1 (pt) |
| HU (1) | HUP0400465A2 (pt) |
| IL (1) | IL159254A0 (pt) |
| MX (1) | MXPA04000494A (pt) |
| NO (1) | NO20040206L (pt) |
| NZ (1) | NZ530043A (pt) |
| PL (1) | PL368053A1 (pt) |
| PT (1) | PT1425280E (pt) |
| RU (1) | RU2310655C2 (pt) |
| SI (1) | SI1425280T1 (pt) |
| WO (1) | WO2003008412A2 (pt) |
| ZA (1) | ZA200309708B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1395591B1 (en) * | 2001-06-12 | 2008-06-04 | Glaxo Group Limited | Corticotropin releasing factor antagonists |
| ATE359782T1 (de) * | 2003-01-16 | 2007-05-15 | Sb Pharmco Inc | Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| GB0308208D0 (en) * | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| MY143499A (en) | 2003-12-22 | 2011-05-31 | Sb Pharmco Inc | Crf receptor antagonist and methods relating thereto |
| ATE430746T1 (de) * | 2004-10-19 | 2009-05-15 | Smithkline Beecham Cork Ltd | Crf-rezeptor-antagonisten und zugehörige verfahren |
| GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| US8088779B2 (en) | 2005-09-30 | 2012-01-03 | Smithkline Beecham (Cork) Limited | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists |
| US8513420B2 (en) | 2007-03-19 | 2013-08-20 | Monika Mazik | Amino-naphthyridine derivatives |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009008552A1 (en) * | 2007-07-11 | 2009-01-15 | Taisho Pharmaceutical Co., Ltd. | 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| RU2015131314A (ru) | 2013-01-18 | 2017-02-27 | Ф. Хоффманн-Ля Рош Аг | 3-замещенные пиразолы и их применение в качестве ингибиторов dlk |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169857A (en) * | 1988-01-20 | 1992-12-08 | Bayer Aktiengesellschaft | 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis |
| NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
| GB2248618B (en) | 1988-06-17 | 1993-01-06 | Wyeth John & Brother Ltd | Process for preparing pyridine derivatives |
| CA2022408A1 (en) | 1989-08-31 | 1991-03-01 | Michael P. Bodman | Process for preparing pyridine carboxylic acid derivatives |
| US5378700A (en) * | 1989-10-11 | 1995-01-03 | Teijin Limited | Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient |
| DE4022414A1 (de) | 1990-07-13 | 1992-01-16 | Bayer Ag | Substituierte pyrrolo-pyridine |
| WO1992012718A1 (en) | 1991-01-23 | 1992-08-06 | Gensia, Inc. | Adenosine kinase inhibitors |
| US5246944A (en) * | 1991-08-13 | 1993-09-21 | Merck & Co., Inc. | Quinoline angiotensin ii antagonists incorporating a substituted benzyl element |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| US5502187A (en) * | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| RU2103272C1 (ru) | 1992-04-03 | 1998-01-27 | Дзе Апджон Компани | Бициклические гетероциклические амины и их фармацевтически приемлемые соли, бициклические гетероциклические амины и их фармацевтически приемлемые соли в качестве ингибитора реакционноспособного кислорода |
| JPH0710876A (ja) | 1993-06-24 | 1995-01-13 | Teijin Ltd | ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン |
| WO1995010506A1 (en) | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| EP0723533A1 (en) * | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| PL181895B1 (pl) | 1994-06-16 | 2001-10-31 | Pfizer | Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL |
| EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| AU738304B2 (en) * | 1995-10-13 | 2001-09-13 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands |
| US5955613A (en) | 1995-10-13 | 1999-09-21 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands |
| BR9710808A (pt) | 1996-08-06 | 1999-08-17 | Pfizer | Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos |
| TW477787B (en) * | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| CN1227554A (zh) | 1996-08-28 | 1999-09-01 | 辉瑞大药厂 | 取代的6,5－杂二环衍生物 |
| AU6279598A (en) | 1997-02-18 | 1998-09-08 | Neurocrine Biosciences, Inc. | Biazacyclic CRF antagonists |
| DE69830409T2 (de) | 1997-08-05 | 2006-01-26 | Pfizer Products Inc., Groton | 4-aminopyrrole[3,2-d]pyrimidine als neuropeptid rezeptor antagonisten |
| JP2002510687A (ja) * | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ |
| JPH11335376A (ja) | 1998-05-25 | 1999-12-07 | Taisho Pharmaceut Co Ltd | アリールテトラヒドロピリジン誘導体 |
| JP2000086663A (ja) | 1998-09-09 | 2000-03-28 | Taisho Pharmaceut Co Ltd | アリールテトラヒドロピリジン誘導体 |
| DE60003899T2 (de) | 1999-03-11 | 2004-05-27 | Neurogen Corp., Branford | Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden |
| JP2002540203A (ja) | 1999-03-29 | 2002-11-26 | ニューロゲン コーポレイション | Ｎｋ−３および／またはｇａｂａ（ａ）受容体リガンドとしての４−置換キノリン誘導体 |
| FR2791675B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| JP2002543200A (ja) | 1999-04-30 | 2002-12-17 | ニューロゲン コーポレイション | ９Ｈ−ピリミド［４、５−ｂ］インドール誘導体：ＣＲＦ１特異性リガンド |
| US6506762B1 (en) | 1999-09-30 | 2003-01-14 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
| US6525067B1 (en) | 1999-11-23 | 2003-02-25 | Pfizer Inc | Substituted heterocyclic derivatives |
| BR0107662A (pt) | 2000-01-18 | 2002-11-19 | Pfizer Prod Inc | Antagonistas do fator de liberação de corticotropina |
| AR028782A1 (es) | 2000-07-05 | 2003-05-21 | Taisho Pharmaceutical Co Ltd | Derivados heterociclicos tetrahidropiridino o piperidino |
| AU2001284417A1 (en) | 2000-09-05 | 2002-03-22 | Taisho Pharmaceutical Co. Ltd. | Hair growth stimulants |
| GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| AR033295A1 (es) * | 2001-04-30 | 2003-12-10 | Glaxo Group Ltd | Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica |
| EP1395591B1 (en) * | 2001-06-12 | 2008-06-04 | Glaxo Group Limited | Corticotropin releasing factor antagonists |
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| ATE359782T1 (de) | 2003-01-16 | 2007-05-15 | Sb Pharmco Inc | Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten |
| EP1592690A1 (en) * | 2003-02-14 | 2005-11-09 | Wyeth | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
-
2001
- 2001-07-17 GB GBGB0117396.2A patent/GB0117396D0/en not_active Ceased
-
2002
- 2002-07-11 GB GB0216041A patent/GB2378702A/en not_active Withdrawn
- 2002-07-15 AT AT06076176T patent/ATE461197T1/de not_active IP Right Cessation
- 2002-07-15 AU AU2002328899A patent/AU2002328899B2/en not_active Ceased
- 2002-07-15 DE DE60214401T patent/DE60214401T2/de not_active Expired - Lifetime
- 2002-07-15 AT AT02764696T patent/ATE338042T1/de not_active IP Right Cessation
- 2002-07-15 KR KR1020097020632A patent/KR20090110386A/ko not_active Application Discontinuation
- 2002-07-15 PT PT02764696T patent/PT1425280E/pt unknown
- 2002-07-15 CN CNB02813866XA patent/CN100447141C/zh not_active Expired - Fee Related
- 2002-07-15 JP JP2003513971A patent/JP4459616B2/ja not_active Expired - Fee Related
- 2002-07-15 DK DK02764696T patent/DK1425280T3/da active
- 2002-07-15 PL PL02368053A patent/PL368053A1/xx unknown
- 2002-07-15 HU HU0400465A patent/HUP0400465A2/hu unknown
- 2002-07-15 WO PCT/EP2002/007865 patent/WO2003008412A2/en active Application Filing
- 2002-07-15 RU RU2004104349/04A patent/RU2310655C2/ru not_active IP Right Cessation
- 2002-07-15 CA CA002451530A patent/CA2451530A1/en not_active Abandoned
- 2002-07-15 NZ NZ530043A patent/NZ530043A/xx unknown
- 2002-07-15 BR BR0211171-3A patent/BR0211171A/pt not_active IP Right Cessation
- 2002-07-15 EP EP06076176A patent/EP1695974B1/en not_active Expired - Lifetime
- 2002-07-15 ES ES02764696T patent/ES2271327T3/es not_active Expired - Lifetime
- 2002-07-15 EP EP02764696A patent/EP1425280B1/en not_active Expired - Lifetime
- 2002-07-15 KR KR1020047000696A patent/KR100961287B1/ko not_active IP Right Cessation
- 2002-07-15 IL IL15925402A patent/IL159254A0/xx unknown
- 2002-07-15 DE DE60235729T patent/DE60235729D1/de not_active Expired - Lifetime
- 2002-07-15 MX MXPA04000494A patent/MXPA04000494A/es active IP Right Grant
- 2002-07-15 ES ES06076176T patent/ES2342417T3/es not_active Expired - Lifetime
- 2002-07-15 US US10/483,792 patent/US7253284B2/en not_active Expired - Fee Related
- 2002-07-15 SI SI200230419T patent/SI1425280T1/sl unknown
-
2003
- 2003-12-15 ZA ZA200309708A patent/ZA200309708B/xx unknown
-
2004
- 2004-01-16 CO CO04002410A patent/CO5550437A2/es not_active Application Discontinuation
- 2004-01-16 NO NO20040206A patent/NO20040206L/no not_active Application Discontinuation
- 2004-11-30 HK HK04109443A patent/HK1066535A1/xx not_active IP Right Cessation
-
2006
- 2006-11-14 CY CY20061101650T patent/CY1105780T1/el unknown
-
2007
- 2007-05-16 US US11/749,433 patent/US20070219232A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0211171A (pt) | Compostos quìmicos | |
| BR0308495A (pt) | Composto, formulação farmacêutica, métodos para ativar receptores de 5-ht1f, para inibir o extravasamento de proteìna neuronal, para tratar ou prevenir enxaqueca em um mamìfero e para preparar um composto, uso de um composto, e, processo para preparar um composto | |
| BR0114323A (pt) | Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto | |
| BRPI0409117A (pt) | compostos n-heterocìclios condensados e seu uso como antagonistas do receptor de crf | |
| BRPI0410714B8 (pt) | derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso | |
| BR122012009489B8 (pt) | processo para produzir 2-etóxi-1-{[2-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso | |
| BRPI0110955B8 (pt) | derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos. | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| UA86617C2 (en) | 2-(1-AZA-BICYCLO[2.2.2]OCT-3-YL)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4-ONE DERIVATIVES AS LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR034448A1 (es) | Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones | |
| ATE457988T1 (de) | A2a-adenosin-rezeptor-antagonisten | |
| BR0015056A (pt) | Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêutico | |
| BR0308162A (pt) | Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso | |
| NO20040589L (no) | Arylsulfonylderivater med 5-HT6 reseptor affinitet. | |
| BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
| ATE401080T1 (de) | (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs | |
| BR0115454A (pt) | Composto de 1-metilcarbapenem ou um sal ou derivado de éster deste farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou de um sal ou derivado de éster deste farmaceuticamente aceitável | |
| ATE397609T1 (de) | Corticotropinfreisetzungsfaktor antagonisten | |
| ATE452636T1 (de) | 3-azabicycloä4.1.0üheptan-derivate zur behandlung von depressionen | |
| EA200600022A1 (ru) | Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций | |
| ATE500833T1 (de) | Pharmazeutische zusammensetzungen zur verhütung oder behandlung von hirnödemen | |
| BR0311932A (pt) | Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado | |
| BR0209035A (pt) | Antagonistas de receptor crf | |
| BR0311839A (pt) | Composto, formulação farmacêutica, método para tratar ou prevenir a resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |